Episode Summary
Executive Summary: Science Friday explores Dr. Rakesh Jain’s decades-long challenge to the cancer “seed and soil” debate: he argues tumors are organs shaped by their microenvironment, and that fixing blood vessels, matrix, pressure, and other “soil” factors can improve drug delivery and treatment response. His work, once dismissed, helped produce multiple FDA-approved therapies and is now expanding into immunotherapy and brain cancer.
Main Topics: Seed-and-soil theory of cancer (Priority: 5/5): The interview centers on Jain’s long-running argument that tumors should be understood not just as cancer cell masses (“seed”), but as organs shaped by surrounding tissue (“soil”). He says the soil influences growth, diagnosis, and therapy resistance. Tumor vasculature and drug delivery (Priority: 5/5): Jain explains that tumor blood vessels are abnormal in both structure and function, causing uneven drug delivery, poor oxygenation, acidity, and resistance to chemotherapy, radiation, and immunotherapy. Engineering approach to cancer biology (Priority: 4/5): His chemical engineering background led him to treat tumor drug delivery as a mass-transfer problem, using mathematical modeling and intravital imaging windows to directly observe flow and treatment in living tumors. Vessel normalization instead of starving tumors (Priority: 5/5): Jain’s controversial shift away from the prevailing anti-angiogenesis/“starve the tumor” dogma argued that some anti-VEGF drugs temporarily normalize vessels, improving perfusion and making other therapies work better. Matrix, pressure, and the tumor microenvironment (Priority: 4/5): He describes how collagen-rich matrix and high interstitial pressure compress vessels, especially in pancreatic cancer, and how reducing matrix abnormality can reopen vessels and improve treatment access. Low-cost repurposed drugs and clinical translation (Priority: 4/5): Jain highlights losartan, a generic blood pressure medication, as a tool to normalize tumor matrix and reduce edema, with potential to improve outcomes in glioblastoma and other diseases. Funding, skepticism, and mentorship (Priority: 4/5): The interview closes on the difficulty of sustaining research amid low grant success rates, visa barriers, and skepticism, while Jain emphasizes mentoring young scientists and persisting despite repeated rejection.
Key Arguments: Tumors are not just collections of cancer cells; they behave more like disordered organs with a microenvironment that actively shapes disease progression and treatment response. Abnormal tumor blood vessels do not simply starve tumors; they also prevent drugs and immune cells from reaching cancer cells effectively. Improving vessel function can make standard and newer therapies work better, including chemotherapy, radiation, and immunotherapy. Direct visualization in living tumors revealed that blood flow is highly heterogeneous, explaining why some regions respond to drugs while others do not. The tumor matrix and high internal pressure physically collapse vessels, especially in pancreatic cancer, where most of the tumor mass is non-cancerous soil. Repurposed, inexpensive drugs such as losartan may normalize tumor conditions and offer a practical translational path, especially where proprietary drug incentives are weak. Long-term scientific persistence can overturn dogma and yield major clinical impact, but only if funding systems support high-risk ideas and early-career researchers.
Data Points: Years studying the tumor microenvironment: Nearly 50 years - Jain describes decades spent focusing on the “soil” rather than the cancer cells FDA-approved treatments linked to his work: 7 - He says his research contributed to seven FDA-approved treatments for diseases including lung and liver cancer National Medal of Science: 2016 - He received the award for his scientific contributions Initial grant rejection count: First 6 grants rejected - He says his early proposals were repeatedly turned down as not important Time from PhD completion to first NIH grant: 1975 to 1980 - He finished his PhD in December 1975 and received his first NIH grant in 1980 Anti-VEGF drug sales: $10+ billion per year - Bevacizumab/Avastin is described as a blockbuster drug originally developed to starve tumors Tumor pressure: >120 mm Hg - He says human tumors can exert pressure above 120 millimeters of mercury, exceeding arterial blood pressure Arterial blood pressure: About 100 mm Hg - Used as comparison for how high tumor pressure can be Pancreatic cancer composition: About 5% cancer cells - He notes most of the tumor is soil, not seed Losartan cost: Less than $1 per day - He describes the blood pressure drug as cheap, safe, and widely used Losartan usage: 20 million people - He notes the drug is already given to a large population Glioblastoma treatment gap: Nearly 20 years - He says the last effective therapy for glioblastoma was almost two decades ago Ongoing trials combining vessel-normalizing drugs: About 200 trials - He says many current studies are testing anti-VEGF combinations with immunotherapy and other agents Grant funding success rate then: About 25% - He says this was the approximate funding rate early in his career Grant funding success rate now: About 4% - He says current funding rates are far lower, especially harmful to junior scientists Grant funding success rate under Biden administration: 11% - He cites this as an intermediate rate before the drop to 4% H-1B fee concern: $100,000 - He warns that charging this amount for H-1B visas would harm universities, industry, and hospitals
Pivotal Quotes: "A tumor is more than a bag of cancer cells. It's like an organ which has gone wry." — Dr. Rakesh Jain: He reframes how listeners should think about tumors and the surrounding microenvironment "When you repair the vessels, immune therapy works better." — Dr. Rakesh Jain: He explains why vessel normalization changed the logic of combining anti-VEGF drugs with immunotherapy "If everything's going right full time, that's just no, there's a little problem here." — Dr. Rakesh Jain: He reflects on scientific uncertainty and the value of being wrong in productive research
Implications: The interview shows that tumor microenvironment research has reshaped cancer care and may expand further through drug repurposing, immunotherapy combinations, and low-cost interventions—but progress depends on stronger funding and support for young scientists.